MX2009003245A - Metodo para generar anticuerpos contra un antigeno resistente, anticuerpos obtenidos por el metodo y sus usos. - Google Patents

Metodo para generar anticuerpos contra un antigeno resistente, anticuerpos obtenidos por el metodo y sus usos.

Info

Publication number
MX2009003245A
MX2009003245A MX2009003245A MX2009003245A MX2009003245A MX 2009003245 A MX2009003245 A MX 2009003245A MX 2009003245 A MX2009003245 A MX 2009003245A MX 2009003245 A MX2009003245 A MX 2009003245A MX 2009003245 A MX2009003245 A MX 2009003245A
Authority
MX
Mexico
Prior art keywords
antibodies
generating active
resistance
tumor
resistant
Prior art date
Application number
MX2009003245A
Other languages
English (en)
Spanish (es)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2009003245A publication Critical patent/MX2009003245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009003245A 2006-09-28 2007-09-27 Metodo para generar anticuerpos contra un antigeno resistente, anticuerpos obtenidos por el metodo y sus usos. MX2009003245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (1)

Publication Number Publication Date
MX2009003245A true MX2009003245A (es) 2009-07-07

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003245A MX2009003245A (es) 2006-09-28 2007-09-27 Metodo para generar anticuerpos contra un antigeno resistente, anticuerpos obtenidos por el metodo y sus usos.

Country Status (21)

Country Link
US (2) US8241646B2 (enExample)
EP (4) EP2497491B1 (enExample)
JP (1) JP5774276B2 (enExample)
KR (1) KR101504770B1 (enExample)
CN (1) CN101516394B (enExample)
AR (1) AR063061A1 (enExample)
AU (1) AU2007312437C1 (enExample)
BR (1) BRPI0717246A2 (enExample)
CA (1) CA2663561A1 (enExample)
FR (1) FR2906533B1 (enExample)
IL (1) IL197790A (enExample)
MA (1) MA30954B1 (enExample)
MX (1) MX2009003245A (enExample)
NO (1) NO20091613L (enExample)
NZ (1) NZ576420A (enExample)
RU (1) RU2515904C2 (enExample)
TN (1) TN2009000102A1 (enExample)
TW (1) TWI516276B (enExample)
UA (1) UA102812C2 (enExample)
WO (1) WO2008046724A1 (enExample)
ZA (1) ZA200902697B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011066417A2 (en) * 2009-11-24 2011-06-03 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
CN106794194A (zh) * 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DE69304895T2 (de) * 1992-02-06 1997-02-06 Merrell Pharma Inc Aufhebung von Multi-Drug-Resistenz durch Tetraarylethylene
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2003275126A1 (en) 2002-09-20 2004-04-08 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
JP2008500269A (ja) * 2003-10-08 2008-01-10 イーバイオサイエンス 天然免疫グロブリン結合試薬とその作製及び使用方法
PL1720540T3 (pl) 2004-02-18 2008-11-28 Gpc Biotech Ag Satraplatyna do leczenia odpornych i opornych nowotworów
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
AU2007312437B2 (en) 2014-01-23
CN101516394A (zh) 2009-08-26
EP2081592A1 (en) 2009-07-29
US8808667B2 (en) 2014-08-19
KR101504770B1 (ko) 2015-03-20
MA30954B1 (fr) 2009-12-01
EP2494984A1 (en) 2012-09-05
TN2009000102A1 (en) 2010-08-19
EP2497491A1 (en) 2012-09-12
US20100146650A1 (en) 2010-06-10
US8241646B2 (en) 2012-08-14
EP2494984B1 (en) 2017-01-04
KR20090057469A (ko) 2009-06-05
ZA200902697B (en) 2010-04-28
HK1131063A1 (en) 2010-01-15
AR063061A1 (es) 2008-12-23
NO20091613L (no) 2009-06-26
JP2010504743A (ja) 2010-02-18
TW200822934A (en) 2008-06-01
JP5774276B2 (ja) 2015-09-09
EP2497491B1 (en) 2017-03-01
FR2906533A1 (fr) 2008-04-04
UA102812C2 (ru) 2013-08-27
IL197790A (en) 2016-10-31
NZ576420A (en) 2012-05-25
US20130028835A1 (en) 2013-01-31
BRPI0717246A2 (pt) 2013-10-08
WO2008046724A1 (en) 2008-04-24
EP2491945B9 (en) 2017-03-08
EP2491945B1 (en) 2016-12-07
AU2007312437C1 (en) 2014-04-10
AU2007312437A1 (en) 2008-04-24
EP2491945A1 (en) 2012-08-29
CN101516394B (zh) 2014-07-30
RU2009114682A (ru) 2010-11-20
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
IL197790A0 (en) 2011-08-01
FR2906533B1 (fr) 2013-02-22
EP2081592B1 (en) 2016-01-13
CA2663561A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
UA102812C2 (ru) Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP4427805A3 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
NZ604003A (en) Monoclonal antibodies against her2
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
SG170080A1 (en) Human monoclonal antibodies to o8e
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2008067283A3 (en) Ovr110 antibody compositions and methods of use
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
WO2012047317A3 (en) Tumor specific antibodies and uses therefor
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
AU2007314522A8 (en) High affinity human antibodies to human IL-4 receptor
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
IN2014MN01879A (enExample)
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
WO2008097866A3 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
MY150709A (en) Human cytomegalovirus neutralising antibodies and use thereof
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration